# Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

> **NCT00556127** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie** · enrollment: 94 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- POOR PROGNOSIS

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Granulocyte-colony-stimulating factor
- **DRUG:** Mitoxantrone
- **DRUG:** Cytarabine ARA-C
- **DRUG:** Dexamethasone
- **DRUG:** Carmustine BCNU
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **RADIATION:** Radiotherapy
- **PROCEDURE:** PBSC reinfusion

## Key facts

- **NCT ID:** NCT00556127
- **Lead sponsor:** Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2007-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556127, "Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00556127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*